Shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) have been given a consensus rating of “Hold” by the fourteen brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $21.20.
ALDR has been the topic of several research analyst reports. BidaskClub lowered Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, May 9th. Cantor Fitzgerald restated a “hold” rating and set a $14.00 target price on shares of Alder Biopharmaceuticals in a research report on Thursday, May 2nd. ValuEngine upgraded Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, January 30th. Zacks Investment Research upgraded Alder Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Tuesday, April 30th. Finally, Canaccord Genuity cut their target price on Alder Biopharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 14th.
In related news, EVP James B. Bucher sold 1,897 shares of the company’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $13.85, for a total transaction of $26,273.45. Following the sale, the executive vice president now owns 11,706 shares in the company, valued at approximately $162,128.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 17.40% of the stock is owned by corporate insiders.
NASDAQ ALDR opened at $11.12 on Monday. Alder Biopharmaceuticals has a 12 month low of $9.44 and a 12 month high of $20.87. The stock has a market capitalization of $921.05 million, a price-to-earnings ratio of -2.28 and a beta of 2.74. The company has a debt-to-equity ratio of 1.21, a quick ratio of 8.34 and a current ratio of 8.34.
Alder Biopharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.47). Equities research analysts expect that Alder Biopharmaceuticals will post -4.47 EPS for the current year.
About Alder Biopharmaceuticals
Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.